Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AERS II Would Be A Module To Fit Into Umbrella Reporting System, FDA Says

This article was originally published in The Tan Sheet

Executive Summary

FDA now plans to develop the AERS II adverse event reporting system as a module that can eventually be incorporated into an agency-wide system

You may also be interested in...



Adverse Events Reporting System Needs Immediate Upgrade – FDA Consultant

FDA should resume an abandoned plan for software acquisition and "immediately" begin the process of upgrading Center for Drug Evaluation and Research's Adverse Events Reporting System, a consultant hired by the agency recommends in a report that is highly critical of the center's efforts to create a second-generation AERS

Sweeping Changes At CDER Recommended In IoM Drug Safety Report

FDA's Center for Drug Evaluation & Research is "an organization in urgent need of great change," the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee concludes in a Sept. 22 final report

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel